Kane Biotech Inc. (KNE.V)
| Previous Close | 0.1400 |
| Open | 0.1500 |
| Bid | 0.1350 x 0 |
| Ask | 0.1400 x 0 |
| Day's Range | 0.1400 - 0.1500 |
| 52 Week Range | 0.0500 - 0.1700 |
| Volume | |
| Avg. Volume | 68,332 |
| Market Cap | 18.552M |
| Beta (5Y Monthly) | 0.55 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.0400 |
| Earnings Date | Aug 27, 2024 - Sept 02, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
GlobeNewswireKane Biotech Receives FDA Approval to Increase Dosage Allowance of its revyve™ Antimicrobial Wound Gel
Paves the Way for Kane’s revyve™ Antimicrobial Wound Gel SprayWINNIPEG, Manitoba, July 23, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (“Kane Biotech”, “Kane” or the “Company”) announces that the US Food and Drug Administration (FDA) has eliminated its usage limitation on the Company’s 510(k) cleared revyve™ Antimicrobial Wound Gel (“revyve™”). Prior to the removal of this restriction, there was a 90 grams/month limit to the amount of revyve™ product that could be admini
- GlobeNewswire
Kane Biotech Receives ISO 13485:2016 MDSAP Quality Certification
Provides access to Canadian, Australian, New Zealand and Brazilian marketsWINNIPEG, Manitoba, July 17, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE; OTCQB:KNBIF) (“Kane Biotech” or “Kane”) announces that it has received ISO 13485:2016 Medical Device Single Audit Program (“MDSAP”) Quality Certification as a designer, developer and manufacturer of medical devices. This achievement speaks to Kane’s demonstrated commitment to bringing quality products to market. These standards require the
- GlobeNewswire
Kane Biotech Announces Issuance of Restricted Share Units
WINNIPEG, Manitoba, July 15, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE; OTCQB:KNBIF), (the “Company” or “Kane Biotech”), today announces that it has issued 4,213,133 restricted share units of the Company (“RSUs”) to various directors, officers, employees and consultants of the Company pursuant to the third amended and restated performance and restricted share unit plan of the Company dated May 22, 2024 (the “PRSU Plan”). Each RSU is exercisable into one common share of the Company (a
